|Volume 6 Issue 138 Published - 14:00 UTC 08:00 EST 17-May-2004 Next Update - 14:00 UTC 08:00 EST 18-May-2004||Editor: Susan K. Boyer, RN
© Vidyya., Inc.
All rights reserved.
Significant benefits of Fuzeon for wide range of pre-treated HIV/AIDS patients
New international consensus guidelines for Fuzeon (enfuvirtide) are published today in AIDS, the official journal of the International AIDS Society. These guidelines are vital because they balance the significant benefits of Fuzeon with the need for self-injection and also provide a clear framework for Fuzeon use.
The independent consensus panel of nine leading experts from around the world agreed that:
"Fuzeon is an important treatment for the increasing number of patients with HIV drug resistance. By providing clear advice on timing of Fuzeon initiation and patient support during therapy, these guidelines clarify the place of this breakthrough drug in current HIV treatment regimens and will enable more pre-treated patients to benefit," stated Dr Mike Youle, Royal Free Hospital, London.